ESR1 and breast neoplasm: Indeed, it is estimated that estrogen receptor isolated from approximately one-third of untreated ER-positive breast tumors is unable to bind its cognate binding site [52], a defect that can be reversed by treating cell extracts with reducing agents such as dithiothreitol [90].